Cargando…
Rational design of a trispecific antibody targeting the HIV-1 Env with elevated anti-viral activity
HIV-1 broadly neutralizing antibodies (bNAbs) are being explored as passively administered therapeutic and preventative agents. However, the extensively diversified HIV-1 envelope glycoproteins (Env) rapidly acquire mutations to evade individual bNAbs in monotherapy regimens. The use of a “single” a...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5830440/ https://www.ncbi.nlm.nih.gov/pubmed/29491415 http://dx.doi.org/10.1038/s41467-018-03335-4 |
_version_ | 1783302995740459008 |
---|---|
author | Steinhardt, James J. Guenaga, Javier Turner, Hannah L. McKee, Krisha Louder, Mark K. O’Dell, Sijy Chiang, Chi-I Lei, Lin Galkin, Andrey Andrianov, Alexander K. A. Doria-Rose, Nicole Bailer, Robert T. Ward, Andrew B. Mascola, John R. Li, Yuxing |
author_facet | Steinhardt, James J. Guenaga, Javier Turner, Hannah L. McKee, Krisha Louder, Mark K. O’Dell, Sijy Chiang, Chi-I Lei, Lin Galkin, Andrey Andrianov, Alexander K. A. Doria-Rose, Nicole Bailer, Robert T. Ward, Andrew B. Mascola, John R. Li, Yuxing |
author_sort | Steinhardt, James J. |
collection | PubMed |
description | HIV-1 broadly neutralizing antibodies (bNAbs) are being explored as passively administered therapeutic and preventative agents. However, the extensively diversified HIV-1 envelope glycoproteins (Env) rapidly acquire mutations to evade individual bNAbs in monotherapy regimens. The use of a “single” agent to simultaneously target distinct Env epitopes is desirable to overcome viral diversity. Here, we report the use of tandem single-chain variable fragment (ScFv) domains of two bNAbs, specific for the CD4-binding site and V3 glycan patch, to form anti-HIV-1 bispecific ScFvs (Bi-ScFvs). The optimal Bi-ScFv crosslinks adjacent protomers within one HIV-1 Env spike and has greater neutralization breadth than its parental bNAbs. Furthermore, the combination of this Bi-ScFv with a third bNAb recognizing the Env membrane proximal external region (MPER) results in a trispecific bNAb, which has nearly pan-isolate neutralization breadth and high potency. Thus, multispecific antibodies combining functional moieties of bNAbs could achieve outstanding neutralization capacity with augmented avidity. |
format | Online Article Text |
id | pubmed-5830440 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-58304402018-03-05 Rational design of a trispecific antibody targeting the HIV-1 Env with elevated anti-viral activity Steinhardt, James J. Guenaga, Javier Turner, Hannah L. McKee, Krisha Louder, Mark K. O’Dell, Sijy Chiang, Chi-I Lei, Lin Galkin, Andrey Andrianov, Alexander K. A. Doria-Rose, Nicole Bailer, Robert T. Ward, Andrew B. Mascola, John R. Li, Yuxing Nat Commun Article HIV-1 broadly neutralizing antibodies (bNAbs) are being explored as passively administered therapeutic and preventative agents. However, the extensively diversified HIV-1 envelope glycoproteins (Env) rapidly acquire mutations to evade individual bNAbs in monotherapy regimens. The use of a “single” agent to simultaneously target distinct Env epitopes is desirable to overcome viral diversity. Here, we report the use of tandem single-chain variable fragment (ScFv) domains of two bNAbs, specific for the CD4-binding site and V3 glycan patch, to form anti-HIV-1 bispecific ScFvs (Bi-ScFvs). The optimal Bi-ScFv crosslinks adjacent protomers within one HIV-1 Env spike and has greater neutralization breadth than its parental bNAbs. Furthermore, the combination of this Bi-ScFv with a third bNAb recognizing the Env membrane proximal external region (MPER) results in a trispecific bNAb, which has nearly pan-isolate neutralization breadth and high potency. Thus, multispecific antibodies combining functional moieties of bNAbs could achieve outstanding neutralization capacity with augmented avidity. Nature Publishing Group UK 2018-02-28 /pmc/articles/PMC5830440/ /pubmed/29491415 http://dx.doi.org/10.1038/s41467-018-03335-4 Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Steinhardt, James J. Guenaga, Javier Turner, Hannah L. McKee, Krisha Louder, Mark K. O’Dell, Sijy Chiang, Chi-I Lei, Lin Galkin, Andrey Andrianov, Alexander K. A. Doria-Rose, Nicole Bailer, Robert T. Ward, Andrew B. Mascola, John R. Li, Yuxing Rational design of a trispecific antibody targeting the HIV-1 Env with elevated anti-viral activity |
title | Rational design of a trispecific antibody targeting the HIV-1 Env with elevated anti-viral activity |
title_full | Rational design of a trispecific antibody targeting the HIV-1 Env with elevated anti-viral activity |
title_fullStr | Rational design of a trispecific antibody targeting the HIV-1 Env with elevated anti-viral activity |
title_full_unstemmed | Rational design of a trispecific antibody targeting the HIV-1 Env with elevated anti-viral activity |
title_short | Rational design of a trispecific antibody targeting the HIV-1 Env with elevated anti-viral activity |
title_sort | rational design of a trispecific antibody targeting the hiv-1 env with elevated anti-viral activity |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5830440/ https://www.ncbi.nlm.nih.gov/pubmed/29491415 http://dx.doi.org/10.1038/s41467-018-03335-4 |
work_keys_str_mv | AT steinhardtjamesj rationaldesignofatrispecificantibodytargetingthehiv1envwithelevatedantiviralactivity AT guenagajavier rationaldesignofatrispecificantibodytargetingthehiv1envwithelevatedantiviralactivity AT turnerhannahl rationaldesignofatrispecificantibodytargetingthehiv1envwithelevatedantiviralactivity AT mckeekrisha rationaldesignofatrispecificantibodytargetingthehiv1envwithelevatedantiviralactivity AT loudermarkk rationaldesignofatrispecificantibodytargetingthehiv1envwithelevatedantiviralactivity AT odellsijy rationaldesignofatrispecificantibodytargetingthehiv1envwithelevatedantiviralactivity AT chiangchii rationaldesignofatrispecificantibodytargetingthehiv1envwithelevatedantiviralactivity AT leilin rationaldesignofatrispecificantibodytargetingthehiv1envwithelevatedantiviralactivity AT galkinandrey rationaldesignofatrispecificantibodytargetingthehiv1envwithelevatedantiviralactivity AT andrianovalexanderk rationaldesignofatrispecificantibodytargetingthehiv1envwithelevatedantiviralactivity AT adoriarosenicole rationaldesignofatrispecificantibodytargetingthehiv1envwithelevatedantiviralactivity AT bailerrobertt rationaldesignofatrispecificantibodytargetingthehiv1envwithelevatedantiviralactivity AT wardandrewb rationaldesignofatrispecificantibodytargetingthehiv1envwithelevatedantiviralactivity AT mascolajohnr rationaldesignofatrispecificantibodytargetingthehiv1envwithelevatedantiviralactivity AT liyuxing rationaldesignofatrispecificantibodytargetingthehiv1envwithelevatedantiviralactivity |